Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
HERTHENA-Lung01
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
- NCT04619004 ↗
- Active, not recruiting
- Daiichi Sankyo
- Deep
We haven't built an HCP commentary report on HERTHENA-Lung01 (patritumab deruxtecan in Non-Small Cell Lung Cancer Metastatic) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HERTHENA-Lung01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 27 | |
| YouTube | 22 | |
| Podcasts | 21 | |
| Bluesky threads | 5 |
The trial
ClinicalTrials.gov- Official title
- HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
- Interventions
- Patritumab Deruxtecan (Fixed dose); Patritumab Deruxtecan (Up-Titration)
- Arms
- Study Group 1: Patritumab deruxtecan 5.6 mg/kg · Experimental
- Study Group 2: Patritumab deruxtecan Up-Titration · Experimental
- Enrollment
- 277
- Primary outcomes
- Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Daiichi Sankyo with Daiichi Sankyo Co., Ltd., Merck Sharp & Dohme LLC
- Start
- Feb 2, 2021
- Primary completion
- Nov 21, 2022
- Results posted
- Yes
- Registry record
- NCT04619004 · updated Sep 1, 2026
Publications
linked from the registry- Yu HA, Goto Y, Janne PA. A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study. Future Oncol. 2026 Oct 12:1-16. doi: 10.1080/14796694.2026.2691681. Online ahead of print. PubMed 42860885
- Patel J, Meng J, Le H, Tanaka Y, Phani S, Salas M, Wu C, Sternberg D, Esker S, Anderson JP, Crowley A, Zhou SQ, Lieb C, Sun H, Doan QV, Santhanagopal A, Reckamp KL. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy. Adv Ther. 2024 Aug;41(8):3299-3315. doi: 10.1007/s12325-024-02936-4. Epub 2024 Jul 3. PubMed 38958845
- Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10. PubMed 37689979
- Yu HA, Yang JC, Hayashi H, Goto Y, Felip E, Reck M, Vigliotti M, Dong Q, Cantero F, Fan PD, Kanai M, Sternberg DW, Janne PA. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncol. 2023 Jun;19(19):1319-1329. doi: 10.2217/fon-2022-1250. Epub 2023 May 22. PubMed 37212796